Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 September 2023 - 2:00PM
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or
“Elicio”), a clinical-stage biotechnology company developing a
pipeline of novel immunotherapies for the treatment of cancer,
today announced that Robert Connelly, Chief Executive Officer, will
present at the upcoming H.C. Wainwright 25th Annual Global
Investment Conference on September 13, 2023 at 9:30 a.m. ET.
A live webcast of the presentation will be accessible to
registered attendees via the company’s Events page. An archived
replay will be available on-demand for 30 days following the
event.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company
developing a pipeline of novel immunotherapies for the treatment of
cancer. By combining expertise in immunology and immunotherapy,
Elicio is engineering investigational Amphiphile (AMP)
immunotherapies intended to precisely target and fully engage the
lymph nodes, the site in our bodies where the immune response is
orchestrated. Elicio is engineering lymph node-targeted AMPlifiers,
immunomodulators, adjuvants and vaccines for an array of aggressive
cancers.
Cautionary Note on Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, known as the PSLRA. These include
statements regarding Elicio’s planned clinical programs, statements
regarding management’s intentions, plans, beliefs, expectations or
forecasts for the future, and the expected participation and
presentation at upcoming conferences; and therefore, you are
cautioned not to place undue reliance on them. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Elicio undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by law. We use words such as “anticipates,”
“believes,” “plans,” “expects,” “projects,” “future,” “intends,”
“may,” “will,” “should,” “could,” “estimates,” “predicts,”
“potential,” “continue,” “guidance,” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. Such
forward-looking statements are based on our expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to Elicio’s
plans to research, develop and commercialize its current and future
product candidates.
New factors emerge from time to time, and it is not possible for
us to predict all such factors, nor can we assess the impact of
each such factor on the business or the extent to which any factor,
or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
These risks are more fully discussed in the current report on Form
8-K that was filed with the SEC on June 2, 2023 and Elicio’s
periodic reports and other documents filed from time to time with
the SEC. Forward-looking statements included in this release are
based on information available to Elicio as of the date of this
release. Elicio does not undertake any obligation to update such
forward-looking statements to reflect events or circumstances after
the date of this release, except to the extent required by law.
Media ContactGloria GasaaturaLifeSci
Communicationsggasaatura@lifescicomms.com+1 646-970-4688
Investor Relations
ContactHeather DiVecchiaElicio TherapeuticsIR@elicio.com+1
857-209-0153
Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024